Physician profile
Robert James Postlewait
NPI 1396907366
$1,881.07
in general payments reported to CMS, 2019-2025
19 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.48 · 2020: $42.54 · 2024: $204 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $529.19 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $309.31 | 2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $166.07 | 2025 | |
| Lilly USA, LLC | $117.10 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Tolmar, INC. | $107.45 | 2025 | Jatenzo |
| Antares Pharma, INC. | $102.53 | 2024-2025 | Xyosted |
| Amgen INC. | $75.91 | 2019-2025 | Otezla, Repatha |
| Amneal Pharmaceuticals LLC | $74.53 | 2025 | Unithroid |
| Corium, LLC | $60.19 | 2025 | Azstarys |
| Glaxosmithkline, LLC. | $55.63 | 2024-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.15 | 2025 | Xifaxan |
| Pfizer INC. | $49.47 | 2024-2025 | |
| Dexcom, INC. | $42.17 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $38.49 | 2020-2025 | Trintellix |
| Abbott Laboratories | $27.52 | 2025 | Freestyle Libre 3 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.29 | 2024 | Jardiance |
| Esperion Therapeutics, INC. | $19.37 | 2025 | Nexletol |
| Biogen, INC. | $18.46 | 2024 | Leqembi |
| Ardelyx, INC. | $17.24 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Postlewait listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.